{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:33Z","timestamp":1792783413382,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Dermira, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,2,13]]},"DOI":"10.1007\/s40257-018-0395-0","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T05:40:43Z","timestamp":1540878043000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials"],"prefix":"10.1007","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct02530281","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02530294","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David M.","family":"Pariser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Quiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanan","family":"Gopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee Anna","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"395_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","volume":"308","author":"J Doolittle","year":"2016","unstructured":"Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308:743\u20139.","journal-title":"Arch Dermatol Res."},{"key":"395_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13555-016-0148-z","volume":"7","author":"DA Grabell","year":"2017","unstructured":"Grabell DA, Hebert AA. Current and Emerging Medical Therapies for Primary Hyperhidrosis. Dermatol Ther (Heidelb). 2017;7:25\u201336.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"395_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000092285","volume":"212","author":"H Hamm","year":"2006","unstructured":"Hamm H, Naumann MK, Kowalski JW, Kutt S, Kozma C, Teale C. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212:343\u201353.","journal-title":"Dermatology."},{"key":"395_CR4","first-page":"25","volume":"37","author":"M Amir","year":"2000","unstructured":"Amir M, Arish A, Weinstein Y, Pfeffer M, Levy Y. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr J Psychiatry Relat Sci. 2000;37:25\u201331.","journal-title":"Isr J Psychiatry Relat Sci."},{"key":"395_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1023\/A:1008968401068","volume":"8","author":"CS Cina","year":"1999","unstructured":"Cina CS, Clase CM. The Illness Intrusiveness Rating Scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res. 1999;8:693\u20138.","journal-title":"Qual Life Res."},{"key":"395_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jaad.2003.12.040","volume":"51","author":"DR Strutton","year":"2004","unstructured":"Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51:241\u20138.","journal-title":"J Am Acad Dermatol."},{"key":"395_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12955-017-0693-x","volume":"15","author":"P Kamudoni","year":"2017","unstructured":"Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients\u2019 daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes. 2017;15:121.","journal-title":"Health Qual Life Outcomes."},{"key":"395_CR8","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.athoracsur.2011.01.105","volume":"91","author":"RJ Cerfolio","year":"2011","unstructured":"Cerfolio RJ, De Campos JR, Bryant AS, Connery CP, Miller DL, DeCamp MM, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. Ann Thorac Surg. 2011;91:1642\u20138.","journal-title":"Ann Thorac Surg."},{"key":"395_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2003.12.029","volume":"51","author":"J Hornberger","year":"2004","unstructured":"Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51:274\u201386.","journal-title":"J Am Acad Dermatol."},{"key":"395_CR10","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1111\/j.1468-3083.2012.04630.x","volume":"27","author":"MA Alvarez","year":"2013","unstructured":"Alvarez MA, Ruano J, Gomez FJ, Casas E, Baamonde C, Salvatierra A, et al. Differences between objective efficacy and perceived efficacy in patients with palmar hyperhidrosis treated with either botulinum toxin or endoscopic thoracic sympathectomy. J Eur Acad Dermatol Venereol. 2013;27:e282\u20138.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"395_CR11","first-page":"392","volume":"17","author":"DA Glaser","year":"2018","unstructured":"Glaser DA, Hebert A, Pieretti L, Pariser D. Understanding patient experience with hyperhidrosis: a national survey in 1,985 patients. J Drugs Dermatol. 2018;17:392\u20136.","journal-title":"J Drugs Dermatol."},{"key":"395_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1600-0846.2007.00282.x","volume":"14","author":"M Brandt","year":"2008","unstructured":"Brandt M, Bielfeldt S, Springmann G, Wilhelm KP. Influence of climatic conditions on antiperspirant efficacy determined at different test areas. Skin Res Technol. 2008;14:213\u20139.","journal-title":"Skin Res Technol."},{"key":"395_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol."},{"key":"395_CR14","first-page":"997","volume":"159","author":"MK Basra","year":"2008","unstructured":"Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997\u20131035.","journal-title":"Br J Dermatol."},{"key":"395_CR15","first-page":"908","volume":"33","author":"N Solish","year":"2007","unstructured":"Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33:908\u201323.","journal-title":"Dermatol Surg."},{"key":"395_CR16","unstructured":"US Food & Drug Administration (FDA). Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009."},{"issue":"5 Suppl","key":"395_CR17","first-page":"S16","volume":"11","author":"DE Glaser","year":"2018","unstructured":"Glaser DE, Hebert AA, Fehnel S, DiBenedetti D, Nelson L, Drew J, et al. Confirmatory psychometric evaluation of the Axillary Sweating Daily Diary: a validated patient-reported outcome measure to assess axillary hyperhidrosis sweating severity J Clin Aesthet Dermatol. 2018;11(5 Suppl):S16\u20137.","journal-title":"Confirmatory psychometric evaluation of the Axillary Sweating Daily Diary: a validated patient-reported outcome measure to assess axillary hyperhidrosis sweating severity J Clin Aesthet Dermatol."},{"key":"395_CR18","doi-asserted-by":"crossref","unstructured":"Nelson L, DiBenedetti D, Pariser D, Glaser D, Hebert A, Hofland H et al. Development and validation of the Axillary Sweating Daily Diary: A patient-reported outcome measure to assess sweating severity. J Patient Rep Outcomes. 2018 (Submitted).","DOI":"10.1186\/s41687-019-0148-8"},{"key":"395_CR19","unstructured":"QBREXZA\u2122 (glycopyrronium) cloth, 2.4% for topical use. Prescribing Information. Dermira, Inc., Menlo Park, CA. 2018."},{"issue":"6 Suppl 1","key":"395_CR20","first-page":"AB105","volume":"76","author":"D Pariser","year":"2017","unstructured":"Pariser D, Hebert AA, Nast A, Werschler WP, Shideler S, Green L, et al. DRM04 for the treatment of primary axillary hyperhidrosis: Primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials [Abstract]. J Am Acad Dermatol. 2017;76(6 Suppl 1):AB105.","journal-title":"J Am Acad Dermatol."},{"key":"395_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.002","author":"DA Glaser","year":"2018","unstructured":"Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.002.","journal-title":"J Am Acad Dermatol."},{"key":"395_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Investig Dermatol. 2005;125:659\u201364.","journal-title":"J Investig Dermatol."},{"key":"395_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27\u201333.","journal-title":"Dermatology."},{"key":"395_CR24","doi-asserted-by":"crossref","unstructured":"Glaser DA, Hebert AA, Nast A, et al. Open-label study (ARIDO) evaluating long-term safety of topical glycopyrronium tosylate (GT) in patients with primary axillary hyperhidrosis. In: Poster presented at the 35th Annual Fall Clinical Dermatology Conference. Las Vegas, NV, 2017.","DOI":"10.25251\/skin.1.supp.94"},{"key":"395_CR25","doi-asserted-by":"crossref","unstructured":"Hebert AA, Glaser D, Green L, Werschler WP, Forsha DW, Drew J, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase 3 randomized controlled trials. Pediatr Dermatol. 2018 (Accepted for publication; in press).","DOI":"10.1111\/pde.13723"},{"key":"395_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5414\/CP201694","volume":"50","author":"WL Chiou","year":"2012","unstructured":"Chiou WL. Low intrinsic drug activity and dominant vehicle (placebo) effect in the topical treatment of acne vulgaris. Int J Clin Pharmacol Ther. 2012;50:434\u20137.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"395_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00403-015-1568-9","volume":"307","author":"SA Lamel","year":"2015","unstructured":"Lamel SA, Sivamani RK, Rahvar M, Maibach HI. Evaluating clinical trial design: systematic review of randomized vehicle-controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne. Arch Dermatol Res. 2015;307:757\u201366.","journal-title":"Arch Dermatol Res."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-018-0395-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0395-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0395-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T18:00:33Z","timestamp":1662314433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-018-0395-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,13]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0395-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"assertion":[{"value":"30 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"ATMOS-1 was conducted in the USA and Germany; ATMOS-2 was conducted in the USA. Trial protocols and informed consent forms were approved by local institutional review boards or independent ethics committees on 13 May 2015, and the first patients were enrolled in July 2015 (ATMOS-1) and August 2015 (ATMOS-2). The trials were registered on ClinicalTrials.gov on 21 August 2015 (ATMOS-1 [NCT02530281] and ATMOS-2 [NCT02530294]). Both trials were carried out in accordance with Good Clinical Practice and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval\/Informed Consent"}},{"value":"These studies were sponsored and funded by Dermira, Inc. All costs associated with the development of this manuscript were funded by Dermira, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DMP has received honoraria for consultancy from Brickell Biotech, Inc., Biofrontera AG, Celgene, Dermira, Inc., DUSA Pharmaceuticals, Inc., LEO Pharma, Novartis, Promius Pharma, LLC, Regeneron Pharmaceuticals, Inc., Sanofi, TheraVida, Inc., and Valeant Pharmaceuticals International, Inc; honoraria for participating on an advisory board for Pfizer, Inc.; investigator grants\/research funding from Abbott Laboratories; Amgen, Inc.; Brickell Biotech, Inc.; Celgene; Dermavant Sciences; Eli Lilly and Company; LEO Pharma; Merck & Co, Inc.; Novartis; Novo Nordisk A\/S; Ortho Dermatologics; Peplin, Inc.; Photocure ASA; Promius Pharma, LLC; Regeneron Pharmaceuticals, Inc.; Stiefel Laboratories; and Valeant Pharmaceuticals International, Inc.; and investigator honoraria from LEO Pharma and Pfizer, Inc. AAH has received investigator research funding from Dermira, Inc. (paid to the UTHealth McGovern Medical School, Houston); advisory board honoraria from Dermira, Inc.; research funding (all monies paid to the UTHealth McGovern Medical School) from Allergan, Plc., Amgen, Inc., Cassiopea, Celgene, Dermavant Sciences, Eli Lilly and Company, Galderma S.A., GSK, Plc., LEO Pharma, Mayne Pharma, Medimetriks Pharmaceuticals, Novan, Inc., Promius Pharma, LLC, and Vanda Pharmaceuticals; honoraria from Amgen, GSK, Plc., Pfizer, Inc., and Valeant Pharmaceutics International, Inc. JD and RG are employees of Dermira, Inc. JQ is a consultant for Dermira, Inc. and an employee of QST Consultations. DAG is a consultant and investigator for Dermira, Inc. and an investigator for Allergan, ATACAMA, Brickell, Galderma, Revance, and Sienna.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}